Exploratory Analysis of the Association Between Plasma Ceramide Alterations and Cognitive Dysfunction in Parkinson's Disease

IF 4.8 1区医学 Q1 NEUROSCIENCES

CNS Neuroscience & Therapeutics Pub Date : 2024-10-20 DOI:10.1111/cns.70082

Xu Liu, Xuanjing Liu, Yuning Liu, Bo Yang, Yangdanyu Li, Fujia Li, Kun Qian, Xuesong Liu, Lishun Xiao, Guiyun Cui, Chuanying Xu

{"title":"Exploratory Analysis of the Association Between Plasma Ceramide Alterations and Cognitive Dysfunction in Parkinson's Disease","authors":"Xu Liu, Xuanjing Liu, Yuning Liu, Bo Yang, Yangdanyu Li, Fujia Li, Kun Qian, Xuesong Liu, Lishun Xiao, Guiyun Cui, Chuanying Xu","doi":"10.1111/cns.70082","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Prior research has underscored the importance of sphingolipid metabolism in Parkinson's disease (PD) pathogenesis. Our objective was to explore the associations between plasma ceramide levels and PD patients with cognitive dysfunction (PD-CD).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We enrolled two study populations from Eastern China and the Parkinson's Progression Markers Initiative (PPMI), comprising 290 (100 HCs, 160 PDs, and 30 MSAs) and 429 (125 HCs and 304 PDs) participants, respectively. The plasma levels of ceramides (Cer 16:0, Cer 18:0, Cer 24:0, and Cer 24:1) were tested via HPLC–MS/MS analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Compared with those in the HC group, the plasma levels of Cer 18:0, Cer 24:1, Cer 16:0/Cer 24:0, Cer 18:0/Cer 24:0, and Cer 24:1/Cer 24:0 were higher in both the PD and MSA groups. Significant differences in the plasma levels of Cer 16:0/Cer 24:0, Cer 18:0/Cer 24:0, and Cer 24:1/Cer 24:0 were observed among the PD-NC (PD with normal cognition), PD-MCI (PD with mild cognitive impairment), and PDD (PD dementia) groups, with the PDD group exhibiting the highest levels. PD patients with higher baseline levels of plasma ceramides (specifically, Cer 18:0, Cer 16:0/Cer 24:0, Cer 18:0/Cer 24:0, and Cer 24:1/Cer 24:0) demonstrated accelerated cognitive decline compared with individuals who had lower baseline plasma ceramide levels during the 5-year follow-up period. A biomarker panel including Cer 18:0/Cer 24:0 and Cer 24:1/Cer 24:0 could effectively differentiate PD-CD from PD-NC with notable diagnostic accuracy.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Our results indicate that plasma ceramide levels could potentially be used as diagnostic biomarkers for PD-CD.</p>\n </section>\n </div>","PeriodicalId":154,"journal":{"name":"CNS Neuroscience & Therapeutics","volume":"30 10","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491299/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Neuroscience & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cns.70082","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Prior research has underscored the importance of sphingolipid metabolism in Parkinson's disease (PD) pathogenesis. Our objective was to explore the associations between plasma ceramide levels and PD patients with cognitive dysfunction (PD-CD).

Methods

We enrolled two study populations from Eastern China and the Parkinson's Progression Markers Initiative (PPMI), comprising 290 (100 HCs, 160 PDs, and 30 MSAs) and 429 (125 HCs and 304 PDs) participants, respectively. The plasma levels of ceramides (Cer 16:0, Cer 18:0, Cer 24:0, and Cer 24:1) were tested via HPLC–MS/MS analysis.

Results

Compared with those in the HC group, the plasma levels of Cer 18:0, Cer 24:1, Cer 16:0/Cer 24:0, Cer 18:0/Cer 24:0, and Cer 24:1/Cer 24:0 were higher in both the PD and MSA groups. Significant differences in the plasma levels of Cer 16:0/Cer 24:0, Cer 18:0/Cer 24:0, and Cer 24:1/Cer 24:0 were observed among the PD-NC (PD with normal cognition), PD-MCI (PD with mild cognitive impairment), and PDD (PD dementia) groups, with the PDD group exhibiting the highest levels. PD patients with higher baseline levels of plasma ceramides (specifically, Cer 18:0, Cer 16:0/Cer 24:0, Cer 18:0/Cer 24:0, and Cer 24:1/Cer 24:0) demonstrated accelerated cognitive decline compared with individuals who had lower baseline plasma ceramide levels during the 5-year follow-up period. A biomarker panel including Cer 18:0/Cer 24:0 and Cer 24:1/Cer 24:0 could effectively differentiate PD-CD from PD-NC with notable diagnostic accuracy.

Conclusions

Our results indicate that plasma ceramide levels could potentially be used as diagnostic biomarkers for PD-CD.

Abstract Image

查看原文本刊更多论文

帕金森病患者血浆神经酰胺变化与认知功能障碍之间关系的探索性分析

研究目的先前的研究强调了鞘脂代谢在帕金森病（PD）发病机制中的重要性。我们的目的是探讨血浆神经酰胺水平与帕金森病认知功能障碍患者（PD-CD）之间的关系：我们招募了华东地区和帕金森病进展标志物倡议（PPMI）的两个研究人群，分别包括 290 名（100 名高危人群、160 名帕金森病患者和 30 名 MSA）和 429 名（125 名高危人群和 304 名帕金森病患者）参与者。通过 HPLC-MS/MS 分析检测了血浆中神经酰胺（Cer 16:0、Cer 18:0、Cer 24:0 和 Cer 24:1）的水平：结果：与 HC 组相比，PD 组和 MSA 组血浆中神经酰胺（Cer 18:0、Cer 24:1、Cer 16:0/Cer 24:0、Cer 18:0/Cer 24:0、Cer 24:1/Cer 24:0）的水平均较高。PD-NC 组（认知正常的帕金森病患者）、PD-MCI 组（轻度认知障碍的帕金森病患者）和 PDD 组（帕金森病痴呆症患者）的血浆中 Cer 16:0/Cer 24:0、Cer 18:0/Cer 24:0 和 Cer 24:1/Cer 24:0 的水平存在显著差异，其中 PDD 组的水平最高。血浆神经酰胺（特别是神经酰胺18:0、神经酰胺16:0/神经酰胺24:0、神经酰胺18:0/神经酰胺24:0和神经酰胺24:1/神经酰胺24:0）基线水平较高的帕金森病患者与血浆神经酰胺基线水平较低的患者相比，在5年的随访期间认知能力下降速度加快。包括神经酰胺18:0/神经酰胺24:0和神经酰胺24:1/神经酰胺24:0在内的生物标记物面板可有效区分PD-CD和PD-NC，诊断准确性显著提高：我们的研究结果表明，血浆神经酰胺水平有可能被用作 PD-CD 的诊断生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CNS Neuroscience & Therapeutics 医学-神经科学

CiteScore

7.30

自引率

12.70%

发文量

240

审稿时长

2 months

期刊介绍： CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation. The journal focuses on neurological and psychiatric diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, epilepsy, and drug abuse.